Cytosorbents Corporation
CTSO
$0.61
$0.023.18%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -73.41% | -262.78% | 231.72% | 80.46% | -173.37% |
| Total Depreciation and Amortization | -3.99% | -8.93% | 8.80% | -4.78% | -0.93% |
| Total Amortization of Deferred Charges | 31.05% | -0.31% | 0.11% | -0.31% | 0.53% |
| Total Other Non-Cash Items | 63.45% | 113.77% | -143.67% | -137.47% | 461.80% |
| Change in Net Operating Assets | -58.72% | -158.39% | 423.97% | 68.81% | -195.40% |
| Cash from Operations | -87.23% | -70.66% | 56.42% | -48.01% | 4.95% |
| Capital Expenditure | -535.29% | 53.93% | -1,657.14% | 96.96% | 54.61% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -459.72% | 175.87% | -110.42% | 18.00% | 62.59% |
| Cash from Investing | -629.09% | 141.73% | -179.24% | 61.94% | 58.53% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | 3,991.08% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 100.00% |
| Cash from Financing | -- | 100.00% | -100.02% | 3,991.08% | 268.69% |
| Foreign Exchange rate Adjustments | 1,025.34% | -156.35% | 900.39% | 124.43% | -224.71% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 51.76% | -92.80% | -141.36% | 239.18% | 13.40% |